Novo Nordisk AS showed its interest in acquiring external research assets by its failed bid for Ablynx NV and that company's blood disorders lead program, earlier this year and, subsequently, the Danish biopharma has not strayed far from its best-selling diabetes and hemophilia sectors when forging new deals, including its latest collaboration, with US biotech Epigen Biosciences.
In a deal worth up to $200m in upfront and milestones to be paid to Epigen, Novo Nordisk has licensed the San Diego, CA-based biotech's LPA1 receptor antagonist, EPGN696, for development in diabetic and chronic kidney disease and other chronic diseases associated with metabolic syndrome
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?